Skip to main content
Clinical Trials/NCT01518660
NCT01518660
Completed
Not Applicable

Multiple Sclerosis - Inflammatory, Neurological and Muscular Adaptations to Progressive Resistance Training

University of Aarhus2 sites in 1 country35 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis (Relapsing Remitting)
Sponsor
University of Aarhus
Enrollment
35
Locations
2
Primary Endpoint
Blood-borne biomarkers
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to investigate underlying mechanisms possibly explaining the beneficial effects of progressive resistance training for people with multiple sclerosis.

Detailed Description

Exercise in general, and progressive resistance training (PRT) in particular, is regarded as an important tool in the rehabilitation of people with multiple sclerosis (MS). Previous studies have reported positive effects of PRT on muscle strength, functional capacity, fatigue and quality of life. Also, a possible disease modifying effect has been proposed. However, the underlying physiological mechanisms that might explain these beneficial effects and the possible effects on disease progression are unresolved. Additionally, none of the previous studies has been concerned with the possible impact of MS progression type, gender and/or medication. The purpose of this randomized, controlled, gender stratified trial is to investigate underlying mechanisms possibly explaining the beneficial effects of progressive resistance training for people with multiple sclerosis.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
January 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed relapsing-remitting MS according to the McDonald criteria
  • Expanded Disability Status Scale (EDSS) between 2.0 and 5.5
  • Be able to train twice a week at the University
  • Use interferon based medication

Exclusion Criteria

  • Alcohol abuse, Alzheimer's and pacemaker (or other metallic implant)
  • Comorbidities like cardiovascular-, respiratory-, orthopaedic or metabolic diseases
  • Having had an attack in a period of 8 weeks prior to the start of the intervention period
  • Having an attack during the intervention period
  • Pregnancy
  • Systematic resistance training in a period of 3 months prior to the start of the intervention period.
  • Training adherence of less than 85%.

Outcomes

Primary Outcomes

Blood-borne biomarkers

Time Frame: Change from baseline to 24 weeks

Resting levels of bloodbourne biomarkers; * Cytokines * Neurotrophins

Secondary Outcomes

  • Brain volume(Change from baseline to 24 weeks)
  • Walking performance(Change from baseline to 24 weeks)
  • Self-reported measures(Change from baseline to 24 weeks)
  • Body Composition(Change from baseline to 24 weeks)
  • Neuro-muscular function of knee extensors(Change from baseline to 24 weeks)
  • Thigh muscle cross-sectional area(Change from baseline to 24 weeks)

Study Sites (2)

Loading locations...

Similar Trials